Incyclix Bio: Funding, Investors & Team (Sep 2026)
Incyclix Bio was established in 2020 in Durham, North Carolina by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman. The company specializes in creating small molecule inhibitors of CDKs for the treatment of advanced and drug-resistant cancers.
Incyclix Bio has raised $16.2M across 2 funding rounds on record, the most recent a Series B of $5.0M announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Incyclix Bio Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Incyclix Bio Funding Rounds
Incyclix Bio raised $11.2M in a Series B announced in Aug 2025.
8 months later, a Series B of $5.0M was announced in Apr 2026.
Incyclix Bio Founders and Leadership Team
Contact details for the Incyclix Bio team: 2 of 2 have an email address on file.
Start 14-day free trial →Incyclix Bio Funding Compared to Other Biotechnology Startups
Incyclix Bio's latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Incyclix Bio in Biotechnology and Durham
Companies Similar to Incyclix Bio
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Incyclix Bio Funding FAQs
What does Incyclix Bio do?
Incyclix Bio was established in 2020 in Durham, North Carolina by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman. The company specializes in creating small molecule inhibitors of CDKs for the treatment of advanced and drug-resistant cancers.
How much funding has Incyclix Bio raised?
Incyclix Bio has raised $16.2M across 2 rounds on record. The most recent is a Series B of $5.0M announced in Apr 2026.
When did Incyclix Bio last raise funding?
Incyclix Bio's most recent funding round on record is a Series B of $5.0M, announced in Apr 2026.
Who founded Incyclix Bio?
FundedIQ lists John Bisi (Founder), Patrick Roberts (Founder) at Incyclix Bio.
Where is Incyclix Bio headquartered?
Incyclix Bio is based in Durham, North Carolina, United States.
How many employees does Incyclix Bio have?
Incyclix Bio is in the 11-50 employee band.
How does Incyclix Bio's funding compare to other Biotechnology startups?
Incyclix Bio's latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Incyclix Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Incyclix Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.